Key result
This review summarizes the efficacies and potential side effects of novel oral direct thrombin inhibitors, such as dabigatran and AZD0837, and oral Factor IXa inhibitors, such as TTP889.
This review summarizes the development and potential of novel oral direct thrombin inhibitors and Factor IXa inhibitors as alternatives to traditional anticoagulants.
These novel agents require randomized trials before clinical consideration; leaves open their role versus established anticoagulants.
The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and could soon be ready to transform the history of coagulation medicine. The first part of this article (published in last month's Expert Review of Hematology) embraced a comprehensive review of oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban, YM150. This second part of the article reviews novel oral direct thrombin inhibitors, such as dabigatran and AZD0837, and a brief description of oral Factor IXa inhibitors, such as TTP889.
No takes yet. Share an insight, caveat, or question.
Rohtesh S. Mehta (2010) conducted a review in Coagulation disorders. Novel oral direct thrombin inhibitors (dabigatran, AZD0837) and Factor IXa inhibitors (TTP889) was evaluated. This review summarizes the efficacies and potential side effects of novel oral direct thrombin inhibitors, such as dabigatran and AZD0837, and oral Factor IXa inhibitors, such as TTP889.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: